Related Experiment Video

Updated: May 12, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

Cigarette smoking and clopidogrel interaction

Kristopher J Swiger1, Omair Yousuf, Kevin P Bliden

  • 1Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Current Cardiology Reports
|April 18, 2013
PubMed

Insights

Smoking may reduce the effectiveness of clopidogrel, a common antiplatelet drug, by affecting how the body processes it. This can lead to higher platelet reactivity, impacting treatment for acute coronary syndromes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitors is crucial for acute coronary syndromes and percutaneous revascularization.
  • Clopidogrel, a widely used P2Y12 inhibitor, exhibits significant inter-individual variability in platelet inhibition.
  • Emerging evidence suggests smoking influences clopidogrel metabolism and on-treatment platelet reactivity.

Purpose of the Study:

  • To investigate the impact of smoking status on clopidogrel efficacy and platelet inhibition.
  • To explore the potential mechanisms, such as CYP1A2 induction, linking smoking to altered clopidogrel response.
  • To review existing evidence on smoking's influence on newer P2Y12 inhibitors like prasugrel and ticagrelor.

Main Methods:

  • Analysis of pharmacodynamic studies evaluating platelet inhibition.
  • Review of post-hoc analyses from major clinical trials assessing clopidogrel efficacy based on smoking status.
  • Examination of mechanistic data related to drug metabolism, particularly cytochrome P450 enzymes.

Main Results:

  • Pharmacodynamic data and clinical trial analyses indicate a correlation between smoking and reduced clopidogrel efficacy.
  • Smokers may exhibit higher on-treatment platelet reactivity when treated with clopidogrel.
  • Cytochrome P450 1A2 (CYP1A2) is hypothesized as a key mediator in the interaction between smoking and clopidogrel metabolism.

Conclusions:

  • Smoking status is a significant factor influencing clopidogrel's effectiveness in patients undergoing DAPT.
  • Understanding this interaction is vital for optimizing antiplatelet therapy in smokers.
  • Further research is needed to clarify the effects of smoking on prasugrel and ticagrelor therapy.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...